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German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany malignancies.AphaseIIIstudybyRummeletal. [4] showed forbendamustine(90mg/m 2 )incombinationwithrituximab aresponserateofmorethan90%andacompleteremission rateofupto47%inpatientswithinpreviouslyuntreatedin-dolent mantel cell lymphoma. Kahl et al. [5] demonstrated thatbendamustine120mg/m 2 asasingleagentinducedaresponse rate of 84% and a complete response of 32% in patientswithrelapsed,rituximab-refractoryindolentNHL.Bendamustineshowedsuperioritytochlorambucilinpatientswith CLL,whichledtoFDAapprovalintheUSlastyear.
Thedegreeofnewevidenceis,sofar,muchlessinbreast cancer. In 2005 we published the largest study on this drug, comparingCMF(cyclophosphamide,methotrexateandfluorouracil) with B(endamustine)MF as first-line treatment for 364 patients with metastatic breast cancer [6] .
Despite a significantincreaseoftimetoprogressionfrom6.7to9.2months infavorforBMF,thisstudydidnotattracttoomuchattention.Itmightbethatthiswasbecauseofthe'oldfashioned' comparatorarm,butalsobecauseitwastooearlyforthereawakening.
More recent approaches now explored better tolerable schedules of bendamustine as monotherapy. Whereas the formerdoseof150mg/m 2 givenon2daysofa4-weekcycle proposedbyHoeffkenetal. [7] wasassociatedwithhighefficacybutalsomuchhighertoxicity,Reichmannetal. [8] more recentlydemonstratedabetternetbenefitforalowerdoseof 120mg/m 2 .Comparisonofefficacybetweenthetwotrialshas tobedonewithcautionbecauseofpotentialdifferencesinthe studypopulations,thesizeofthestudiesaswellasimprovementsinresponseassessmentovertime.
InthisissueofOnkOlOgieSteinbildetal. [9] nowreporton another possibility how bendamustine might be given to patientswithadvancedmetastaticbreastcancer.Theyconducted a phase II study on 22 patients, who have been pre-treated predominantly with anthracycline and/or taxane containing Duringthelastdecadesthetreatmentofbreastcancerhasbecome extremely diversified. This is not only due to the new understanding of molecular subtypes (luminal, basal, HER2 positive) but also due to an increasing armamentarium of drugsshowingactivityinallstagesofthisdisease.Thisallows ustodaytotreatmoreandmorepatientswithmetastaticdiseasewitheven10ormorelinesofdifferentendocrine,cytotoxic,ortargetedmono-orcombinationtreatments.Whereas the main goal of treatment in metastatic breast cancer is, of course,toimproveoverallsurvival,qualityoflifeorthetime without symptoms, toxicity becomes increasingly important with advanced disease. With this, even more possibilities to controldiseaseandsymptomswithoutcompromisingquality oflifebytoxicitiesorstressfuladministrationarewarranted. Thereforewehavetoask:mightbendamustineprovideafurtherpossibilitytotreatbreastcancerpatients?
BendamustinewassynthesizedintheformerGermanDemocraticRepublic(GDR)inthe1960s.Theintentionwastoproduceanitromustardcompoundthatwaslesstoxicbutatleast aseffectiveasalkylatingagents.Thiswasdonebyrelocating anitrogenmustardgrouptoadifferentposition [1] .Itturned outthatthisdrugnotonlyhadfeaturesofanalkylatingagent butalsoofapurineanalogue.Itshowsahigherstabilityand causes longer-lasting DNA damage. In vitro, and now also clinically,itdoesnotshowcrossresistancetootheralkylating agents [2, 3] .
It was widely used in the GDR for the treatment of lymphoidmalignancies,suchasnon-Hodgkin'slymphoma(NHL), chroniclymphocyticleukemia(CLL),multiplemyeloma,and Hodgkin'slymphoma,aswellasbreastcancer.However,after thereunification,itlostapprovalforbreastcancerduetoinsufficientsafetyandefficacydataaccordingtomodernstandards.
However,recentlythedrughasattractedsignificantattentionduetoanumberofpositivestudiesinvariouslymphatic This study demonstrates that bendamustine provides another opportunity for the treatment of patients with far advanced disease, where single-agent chemotherapy is the appropriate type of therapy. However, if we really want to establishthisdruginearlierstagesofdisease,dataoncombinationswithotheractivedrugsareneeded.Wehaverecently establishedthedoseofbendamustinewhengivenincombinationwithpaclitaxel,andfoundthatbothdrugscanbegiven together without dose compromises [13] . The RiTa trial is currently continued as a phase II study using recommended dosesof70mg/m 2 bendamustineand90mg/m 2 paclitaxel.An AmericangroupinOhioiscurrentlyinvestigatingthecombinationofbendamustinewitherlotinib [14] .
Unfortunately,thefocusofclinicaltrialsactivitieswiththis drugisinlymphaticdiseases(29outof39registeredtrialsin theclinicaltrials.govregistry).However,astheeconomiclife cycleofthiscompoundhasalreadyreacheditsceiling,itappearslessprobablethatalargeplanfordevelopmentinbreast cancerexistsorwillbesetupbasedonthesenewandpromisingdata.Itwillbeuptocollaborativeresearchgroupstofurther investigate the potential of this multi-targeted agent in thefieldofbreastcancer.
